Molecular Profile | FGFR1 act mut |
Therapy | Brivanib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | no benefit |
Create By | c-tyin |
Update By | spatt |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | FGFR1 act mut | Advanced Solid Tumor | no benefit | Brivanib | Preclinical | Actionable | In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366). | 22238366 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(22238366) | Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. | Full reference... |